Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $21.00.

Several brokerages recently weighed in on TLX. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 7th.

Telix Pharmaceuticals Trading Up 1.7%

Shares of TLX stock opened at $6.54 on Friday. Telix Pharmaceuticals has a 1 year low of $6.34 and a 1 year high of $30.36. The business’s fifty day moving average is $7.79 and its 200-day moving average is $9.47.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently made changes to their positions in the business. Portland Investment Counsel Inc. boosted its stake in Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after acquiring an additional 138,200 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals in the third quarter valued at approximately $243,000. Millennium Management LLC acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth approximately $1,883,000. Lazard Asset Management LLC acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth about $1,097,000. Finally, Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 67.3% during the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.